Biotech investors wary of Warren tax proposals

Why biotech investors think Warren’s plan could disincentivize long-term investing

Biotech investors are concerned that Sen. Elizabeth Warren’s plans for funding Medicare for All could disincentivize the long-term investments that are the industry’s lifeblood. They are especially worried about unintended consequences of a proposal to tax capital gains annually, rather than when assets are sold.

Warren (D-Mass.) wants to

Read the full 486 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE